This company seems to have been delisted
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Clovis Oncology
CLVS
₹6.96
Share price
0.00%
Change (1 day)
-94.95%
Change (1 year)
Categories
Clovis Oncology (CLVS) - Total debt
Total debt on the balance sheet as of September 2022 : ₹58.38 Billion
According to Clovis Oncology's latest financial reports the company's total debt is ₹58.38 Billion. A company’s total debt is the sum of all current and non-current debts.
Clovis Oncology - Total debt on balance sheet (from 2011 to 2022)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2021-12-31 | ₹47.51 B | 0.43% |
| 2020-12-31 | ₹47.31 B | -7.16% |
| 2019-12-31 | ₹50.96 B | 26.42% |
| 2018-12-31 | ₹40.31 B | 123.55% |
| 2017-12-31 | ₹18.03 B | -5.61% |
| 2016-12-31 | ₹19.10 B | 2.71% |
| 2015-12-31 | ₹18.59 B | 2.08% |
| 2014-12-31 | ₹18.22 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | ₹51.63 B | -11.56% | 🇺🇸 USA |
 AstraZeneca AZN | ₹2.684 T | 4,497.87% | 🇬🇧 UK |
 Pfizer PFE | ₹5.257 T | 8,905.17% | 🇺🇸 USA |
 Johnson & Johnson JNJ | ₹4.481 T | 7,577.12% | 🇺🇸 USA |
 AbbVie ABBV | ₹5.994 T | 10,168.43% | 🇺🇸 USA |
 Eli Lilly LLY | ₹3.303 T | 5,558.94% | 🇺🇸 USA |